“Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s91, https://doi.org/10.25251/skin.4.supp.91.